126229-12-7

Basic information

• Product Name: ManidipineHcl
• Synonyms: ManidipineHcl;3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-, 2-(4-(diphenylmethyl)-1-piperazinyl)ethyl methyl ester, dihydrochloride, (+-)-;Ccris 3484
• CAS NO: 126229-12-7
• Molecular Formula: C₃₅H₃₈N₄O₆*2ClH
• Molecular Weight: 683.6213
• Mol File: 126229-12-7.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: ManidipineHcl(CAS DataBase Reference)
• NIST Chemistry Reference: ManidipineHcl(126229-12-7)
• EPA Substance Registry System: ManidipineHcl(126229-12-7)

Safety Data

• Hazardous Substances Data: 126229-12-7(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
ManidipineHcl is used as an antihypertensive agent for the treatment of hypertension. It helps in lowering systolic blood pressure in a dose-dependent manner, providing long-lasting effects. Its minimal cardiodepressant activity makes it a safer option for hypertensive patients who may be at risk of cardiac failure or severe bradycardia.
Used in Cardiovascular Applications:
ManidipineHcl is used as a calcium channel blocker to improve cardiovascular health. By blocking the movement of calcium ions into heart and blood vessel cells, it helps in relaxing the blood vessels, which in turn reduces blood pressure and the workload on the heart. This makes it a valuable asset in managing and treating various cardiovascular conditions, including hypertension and angina.
Brand Name:
ManidipineHcl is commercially available under the brand name Calslot.

Originator

Takeda (Japan)

Upstream product

• 99-61-6 3-nitro-benzaldehyde 
• 105-45-3 acetoacetic acid methyl ester 
• 90096-33-6 2-(4-diphenylmethyl-1-piperazinyl)ethyl 3-aminocrotonate 
• 39562-17-9 methyl 2-(3-nitrophenylmethylene)acetoacetate 
• 10527-64-7 1-diphenylmethyl-4-(2-hydroxyethyl)piperazine 
• 89226-49-3 2-(4-diphenylmethyl-1-piperazinyl)ethyl acetoacetate 
• 89226-50-6 manidipine 
• 841-77-0 diphenylmethylpiperazine 
• 88712-56-5 methyl (R)-5-chlorocarbonyl-2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3-carboxylate 
• 76093-34-0 (+)-(S)-1,4-dihydro-2,6-dimethyl-5-methoxycarbonyl-4-(3-nitrophenyl)pyridine-3-carboxylic acid 
• 76093-31-7 1-ethoxymethyl-1,4-dihydro-5-methoxycarbonyl-2,6-dimethyl-4-(3-nitrophenyl)-pyridine-3-carboxylic acid 
• 76093-32-8 (4S)-1-ethoxymethyl-1,4-dihydro-5-methoxycarbonyl-2,6-dimethyl-4-(3-nitrophenyl)-3-pyridinecarboxylic acid 
• 88712-56-5 methyl (R)-5-chlorocarbonyl-2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3-carboxylate 
• 76093-33-9 (R)-5-(methoxycarbonyl)-2,6-dimethyl-4-(m-nitrophenyl)-1,4-dihydropyridine-3-carboxylic acid 

Downstream Products

• 104305-93-3 2-(4-diphenylmethyl-1-piperazinyl)ethyl methyl 2,6-dimethyl-4-(3-nitrophenyl)-3,5-dicarboxylate 
• 89226-50-6 manidipine 
• 120092-68-4 (R)-Manidipine 
• 126451-47-6 (S)-Manidipine 

Relevant articles and documents

Improved manidipine dihydrochloride II crystal form production method

The invention discloses an improved manidipine dihydrochloride II crystal form production method. The method comprises the steps: adding concentrated grease containing manidipine alkali into ethyl alcohol, stirring to befor crystallizedcrystallizing, filtering to obtain filter cake and pulping and washing to obtain the manidipine alkali; then utilizing hydrochloric acid salification to obtain a manidipine dihydrochloride crude product; heating and dissolving the manidipine dihydrochloride crude product by methyl alcohol containing water, performing thermal-insulation filtration, crystallization and filtration, collecting separated-out crystal and drying to obtain the manidipine dihydrochloride II crystal form. The purity of the II crystal form obtained by the production method disclosed bythe invention is larger than 99.8%, and the method has very great guiding significance in researches of the manidipine dihydrochloride crystal form and clinical application of manidipine dihydrochloride.

Multiple crystal forms of S-Montelukast sodium and preparation method thereof

The invention relates to multiple crystal forms of S-Montelukast sodium and a preparation method thereof, in particular to a crystal form II, a crystal form III and a crystal form IV of S-Montelukast sodium, the preparation method of the crystal forms, pharmaceutical composition containing the crystal forms and a medical application of the crystal forms and the pharmaceutical composition. The crystal form II, the crystal form III and the crystal form IV of S-Montelukast sodium have excellent physicochemical properties and good stability, and are suitable for a preparation technological process and long-term storage. The pharmaceutical composition adopting compounds in the crystal forms as active components can be used for treating diseases such as hypertension and the like.

S-Manidipine hydrochloride crystal form I and preparation method thereof

The invention relates to an S-Manidipine hydrochloride crystal form I and a preparation method thereof. The preparation method includes: dissolving S-Manidipine free alkali into alcohols or alcohol/water, salifying with HCL, and crystallizing to obtain S-Manidipine hydrochloride crystal which is determined as the crystal form I according to X-ray powder diffraction detection. Products of the S-Manidipine hydrochloride crystal form I have excellent temperature and humidity stability, meet quality requirements on residual solvent and moisture and are suitable for preparation process and long-term storage. Pharmaceutical compositions with compounds of the crystal form I serving as active ingredients can be used for treating diseases such as hypertension and the like.

Polymorphic Forms of Manidipine

The invention relates to various new polymorphic forms of manidipine and pharmaceutically acceptable salts thereof. The invention also relates to processes for the preparation of the polymorphic forms of manidipine and pharmaceutically acceptable salts thereof.

POLYMORPHIC FORMS OF MANIDIPINE

The invention relates to various new polymorphic forms of manidipine and pharmaceutically acceptable salts thereof. The invention also relates to processes for the preparation of the polymorphic forms of manidipine and pharmaceutically acceptable salts thereof.

Substituted heterocyclylalkyl esters of 1,4-dihydropyridine-3,5-dicarboxylic acids

Dihydropyridine derivatives and acid addition salts thereof which are of use as prophylactic or/and therapeutic drugs for cardiovascular diseases, said dihydropyridine derivatives having the formula STR1 wherein R1, R2 and R3 are the same or different and each is alkyl, cycloalkyl, cycloalkylalkyl or alkoxyalkyl; R4 and R5 are the same or different and each is hydrogen, halogen, nitro, trifluoromethyl, alkyl, cycloalkyl, alkoxy, cyano, alkoxycarbonyl or alkylthio; R6 is hydrogen, alkyl, cycloalkyl, aralkyl, aryl or a pyridyl; X is oxygen, sulfur, vinylene, azomethine or a group of the formula STR2 A is alkylene; Ar is aryl or a pyridyl; m is an integer of 1 to 3; n is an integer of 0 to 2.